LUPKYNIS US Registry Trial

Rheumatology
Sheetal Desai
A Prospective Observational Registry of Patients Treated With LUPKYNIS (Voclosporin) in the US
Rheumatology

Study Description

Eligibility

Lupus nephritis (LN) confirmed by biopsy

Initiating or have initiated treatment with commercial LUPKYNIS as per US approved Prescribing Information (PI)

Written informed consent

  • Off-label use (Use of LUPKYNIS outside of the FDA-approved US Prescribing Information)
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.